NetApp Joins Aston Martin Cognizant Formula One Team to Pioneer Data-Driven Racing Strategy
1.3.2021 16:00:00 EET | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global cloud-led, data-centric software company, and Aston Martin Cognizant Formula One™ today announced a multi-year partnership as the world-famous car company gears up for its return to Formula One competition. After more than 60 years away, the British car brand returns to the F1™ grid, supported by NetApp, with a new edge: an innovative approach to racing utilizing the power of data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210301005160/en/
NetApp Joins Aston Martin Cognizant Formula One Team to Pioneer Data-Driven Racing Strategy (Graphic: Business Wire)
The partnership with NetApp reinforces Aston Martin Cognizant Formula One Team’s commitment to unlocking the very best of cloud by outfitting the team with world-class data and cloud services. Broad and ambitious in scope, the partnership will focus on maximizing performance both on and off the track.
From trackside to factory to cloud, the data used to inform Aston Martin Cognizant Formula One Team’s racing strategies will be available in real time on a global scale. With a data fabric powered by NetApp, the team will be able to extract more value from their data to better gauge car performance and address necessary refinements before, during, and after each race.
This data fabric will also help reduce operational complexities, while ensuring data compliance, security, and protection of the team’s intellectual property. By standardizing on NetApp across all platforms, the British racing team will be able to maximize resource utilization and remove inefficient data silos, enabling costly IT investments to be diverted back into car and team development.
“We are thrilled to partner with Aston Martin Cognizant Formula One as it embarks on a highly ambitious data journey in pursuit of greater speed, higher reliability and unmatched efficiency,” said James Whitemore, chief marketing officer at NetApp. “By tapping into our 28 years of data-centric innovation, we are proudly supporting the team as they push the boundaries of continuous performance improvement beyond the finish line.”
“Formula One teams have always been pioneers in analyzing data for a competitive advantage, especially when milliseconds mean the difference between pole position and starting somewhere in the middle of the pack,” said Otmar Szafnauer, chief executive officer and team principal at Aston Martin Cognizant Formula One. “The team’s partnership with NetApp, along with title partner Cognizant, represents a new stage in our journey of continuous improvement. We are excited to introduce NetApp as we strive to make everything we do faster and smarter. By empowering our brilliant team of people with NetApp’s industry-leading data solutions, we are ushering in a new era of racing where we can constantly evolve to be a faster, smarter and more exciting team.”
About NetApp
NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc.
About Aston Martin Cognizant Formula One Team
After more than 60 years away from Formula One, Aston Martin returns to Grand Prix racing in 2021. With one of the most iconic emblems in the world above the garages and a team of almost 500 passionate men and women at its heart, this is a team with both a rich heritage and a fresh perspective – bringing new energy to the sport with a determination to shake up the order and compete at the sharp end.
Our mission is to use the global platform of motorsport to engage a new wave of fans – showcasing the technology and innovation which live at our core while representing the values that resonate with the changing world in which we live.
The new age of Aston Martin Cognizant Formula One Team begins here.
www.astonmartinf1.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005160/en/
Contact information
NetApp
Media Contact:
Chris Drago
NetApp
1 (831) 900-8889
chris.drago@netapp.com
NetApp Investor Contact:
Lance Berger
NetApp
1 (408) 822-6628
lance.berger@netapp.com
Aston Martin Cognizant Formula One Team Media Contacts:
Matt Bishop
Chief Communications Officer
+44 7976 835878
Matt.Bishop@astonmartinf1.com
Will Hings
Head of Media & Communications
+44 7734 202020
Will.Hings@astonmartinf1.com
Joanne Revill
Senior Media Officer
+ 44 7408 901384
Joanne.Revill@astonmartinf1.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom